NCT04771754View on ClinicalTrials.gov

The Effect of Dolutegravir on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

March 20, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

January 10, 2024

Conditions

HIV-1-infection on Healthy Volunteers

Interventions

DRUG

Dolutegravir

50 mg once daily orally

Trial Locations (1)

SW10 0XD

Arnold Xhikola, London

All Listed Sponsors

lead

Chelsea and Westminster NHS Foundation Trust

OTHER